Evidence map›Paper›PMID 40057797›Full record

ArticleActa neuropathologica communications2025

DNA methylation profiling from cerebrospinal fluid as a diagnostic tool for pineoblastoma.

Celeste Antonacci, Luana Abballe, Sara Patrizi, Lucia Pedace, Sabina Barresi, Isabella Giovannoni, Chantal Tancredi, Flavia Vinciarelli, Giacomina Megaro, Andrea Carai and 4 more

Abstract readCase Reports
In one paragraph

Article in Acta neuropathologica communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Celeste Antonacci *Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Luana Abballe *Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. luana.abballe@opbg.net.
Sara PatriziOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Lucia PedaceOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Sabina BarresiPathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Isabella GiovannoniPathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Chantal TancrediPathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Flavia VinciarelliOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Giacomina MegaroOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Andrea CaraiNeurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Sabrina RossiPathology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Franco LocatelliOnco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Angela Mastronuzzi *Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Evelina Miele *Onco-Hematology, Cell Therapy, Gene Therapies and Hemopoietic Transplant, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy. evelina.miele@opbg.net.

Funding

Ministero della Salute Ricerca Finalizzata GR-2018-12367328Ricerca Corrente 5x1000 202205_ONCO_MIELE
6 · The paper itself

Abstract

Pineoblastoma is a rare and aggressive malignancy that often affects pediatric populations. Accurate diagnosis is challenging due to histological overlap with other central nervous system tumors and limited molecular data. DNA methylation profiling and analysis of circulating tumor DNA (derived from both cell dissemination as well as cell-free- cfDNA) in cerebrospinal fluid (CSF) are emerging tools for precise tumor classification, in the field of pediatric central nervous system tumors. Here, we report a challenging case of a 17-year-old refugee girl with a previous diagnosis of a primitive neuroectodermal tumor. Formalin-fixed, paraffin-embedded tissue was not available for histopathological re-evaluation. However, the methylation profiling of low amount of CSF-derived DNA classified the tumor as "pineoblastoma, subtype miRNA processing altered 1, subclass A," enabling patient management. The diagnosis was later confirmed through tissue-based DNA methylation analysis of a secondary lesion, demonstrating that the epigenetic signature faithfully reflected tumor features. This case report highlights the potential of CSF-based DNA methylation profiling as a minimally invasive yet accurate diagnostic tool for pediatric CNS tumors. The concordance between CSF and tissue profiling supports the integration of liquid biopsy into diagnostic workflows, allowing for earlier diagnosis and personalized treatment strategies. However, more studies are needed to demonstrate the reliability of our approach in other CNS malignancies.

Indexed as

Brain NeoplasmsDNA MethylationPineal GlandPinealomaAdolescentFemaleHumansCerebrospinal fluidDiagnosisDNA methylationLiquid biopsyPineoblastoma

Identifiers

PMID40057797
PMCPMC11889783

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.